Paul Stuka Purchases 20,000 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka bought 20,000 shares of the stock in a transaction dated Wednesday, May 27th. The shares were purchased at an average cost of $0.88 per share, for a total transaction of $17,600.00. Following the completion of the transaction, the director directly owned 667,871 shares of the company’s stock, valued at $587,726.48. This trade represents a 3.09% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka bought 10,000 shares of InspireMD stock. The shares were purchased at an average cost of $1.19 per share, for a total transaction of $11,900.00.
• On Friday, May 8th, Paul Stuka bought 65,626 shares of InspireMD stock. The shares were purchased at an average cost of $1.16 per share, for a total transaction of $76,126.16.
• On Thursday, May 7th, Paul Stuka bought 6,378 shares of InspireMD stock. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $7,334.70.
• On Wednesday, May 6th, Paul Stuka bought 1,517 shares of InspireMD stock. The shares were purchased at an average cost of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Stock Up 2.3%

Shares of NYSE:NSPR opened at $0.92 on Friday. InspireMD, Inc. has a twelve month low of $0.86 and a twelve month high of $2.93. The stock’s 50 day moving average is $1.30 and its 200-day moving average is $1.62. The firm has a market capitalization of $43.12 million, a price-to-earnings ratio of -1.23 and a beta of 0.82.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday, May 4th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Maxim Group assumed coverage on InspireMD in a research report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target for the company. Finally, Loop Capital set a $5.00 price target on InspireMD in a research report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, InspireMD currently has a consensus rating of “Buy” and an average target price of $4.50.

Institutional Investors Weigh In On InspireMD

A number of institutional investors and hedge funds have recently bought and sold shares of NSPR. Renaissance Technologies LLC purchased a new stake in InspireMD in the 1st quarter valued at $29,000. XTX Topco Ltd purchased a new stake in InspireMD in the 4th quarter valued at $30,000. Virtu Financial LLC purchased a new stake in InspireMD in the 4th quarter valued at $31,000. Creative Planning purchased a new stake in InspireMD in the 2nd quarter valued at $44,000. Finally, Legato Capital Management LLC purchased a new stake in InspireMD in the 4th quarter valued at $48,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.